Exploiting FLVCR1-mediated choline transport in acute myeloid leukemia
Active Grant Awarded
- Award ID
- R01CA316048
- Recipient
-
Seattle Children's Hospital UEI SZ32VTCXM799
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $597,193
Award facts
- Assistance listing
- 93.396 Cancer Biology Research
- Completion date 4% complete
- Place of performance
- Seattle, WA 98101, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Seattle Children's Hospital, doing business as Seattle Children's Research Institute, a grant totaling $597,193 on September 10, 2026, under the Cancer Biology Research program (CFDA 93.396). The grant funds research under Grant R01CA316048 on FLVCR1-mediated choline transport in acute myeloid leukemia (AML), focusing on the CBFA2T3-GLIS2 (CG) fusion subtype, which the project summary describes as one of the most aggressive AML subtypes, with an overall survival rate of only 15-30%. Preliminary data show CG AML cells rely on FLVCR1-mediated choline uptake for survival, while many other AML subtypes do not.
The project has three specific aims. Aim 1 examines how FLVCR1-mediated choline supply supports AML survival, with a focus on mitochondrial physiology. Aim 2 defines compensatory choline uptake pathways and identifies molecular regulators that dictate FLVCR1 dependency in AML. Aim 3 assesses the role of FLVCR1-mediated choline transport in human hematopoietic stem and progenitor cells.
The full obligated amount is $597,193. The period of performance runs from the September 10, 2026 award date to an ultimate completion date of August 31, 2031. Work is performed in Seattle, WA 98101. The assistance type is grant. The Cancer Biology Research program supports fundamental information on the cause and nature of cancer to inform better methods of prevention, detection, diagnosis, and treatment of neoplastic diseases.
Description
- Abstract
- Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy, and effective therapies are lacking for many disease subgroups. AML driven by the CBFA2T3-GLIS2 (CG) fusion represents one of the most aggressive subtypes, with an overall survival rate of only 15-30%. These patients frequently relapse and exhibit resistance to standard chemotherapies, highlighting the urgent need for new therapeutic strategies. Through genome-scale crispr screens, we identified the solute carrier FLVCR1 as a strong selective dependency in CG AML. FLVCR1 was originally discovered as a heme exporter essential for erythropoiesis, while recent studies uncovered its role as a choline transporter, providing an essential precursor for phospholipids that compose cellular membranes. The functional relevance of FLVCR1 in cancer, however, has not been well understood. Although elevated choline metabolism has been observed in various cancer types, the mechanisms by which tumor cells acquire choline remain to be elucidated. Our preliminary data demonstrates that CG AML cells rely on FLVCR1-mediated choline uptake for survival, whereas many other AML subtypes are FLVCR1-independent, suggesting distinct strategies of choline supply. This proposal seeks to define the role of FLVCR1-mediated choline uptake across AML and normal hematopoiesis, with a goal to uncover fundamental mechanisms of choline acquisition in cancer and provide insights into how FLVCR1 coordinates its various functions. Specific aim 1 will investigate how FLVCR1-mediated choline supply supports AML survival, with a focus on mitochondrial physiology. Specific aim 2 will define compensatory choline uptake pathways and identify molecular regulators that dictate FLVCR1 dependency in AML. Specific aim 3 will assess the role of FLVCR1-mediated choline transport in human hematopoietic stem and progenitor cells and use the structure-guided mutants of FLVCR1 to deconvolute its choline versus heme transport functions. Given the limited availability of in vitro models for CG AML and human hematopoiesis, together with the potential influence of the in vivo microenvironment on choline metabolism, orthotopic xenograft mouse models will be incorporated throughout the study to strengthen the physiological relevance and robustness of our findings. In particular, patient-derived xenograft models of CG AML, which most faithfully recapitulate the molecular and phenotypic features of the primary disease, will be used to validate key findings. Together, these studies will reveal important principles of choline metabolism in cancer and point to new therapeutic strategies for targeting CG AML that may extend to other FLVCR1- dependent cancers.
Quick answers
Who received award R01CA316048?
R01CA316048 was awarded to Seattle Children's Hospital by National Cancer Institute (National Institutes of Health) on September 10, 2026.
How much is award R01CA316048 worth?
$597,193 has been obligated on R01CA316048.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award